trial

DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia

NCTId NCT02532686
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 40 (actual)
Sponsored by China Medical University Hospital
Primary completion 2016-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2014-10
Primary completion
2016-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
DAAOI-2

Sponsors

China Medical University HospitalLead Sponsor
Ministry of Science and Technology, TaiwanCollaborator

Sites

1 total
Taichung, Taiwan

Linked catalysts

1
DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia — primary completion2016-07

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE2
Primary Completion Date
2016-07
Status
COMPLETED
relationships
The graph out of here
drug
DAAOI-2
drug
lead_sponsor
China Medical University Hospital
company
collaborator
Ministry of Science and Technology, Taiwan
company
indication
Schizophrenia
indication
Schizophrenia
indication